Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025

Key Takeaways:

• Bristol Myers Squibb will present new real-world and clinical data on Camzyos (mavacamten) at the ESC Congress 2025 in Madrid.
• Camzyos is the first and only approved cardiac myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy.
• The ODYSSEY-HCM trial, involving 580 adults with non-obstructive HCM, is the largest completed study of its kind.
• Real-world data from COLLIGO-HCM spans diverse patient populations.
• The BMS-Pfizer Alliance will also present new research findings on Eliquis (apixaban).

Introduction

Bristol Myers Squibb (BMS) plans to unveil significant updates on its cardiovascular therapies at the European Society of Cardiology (ESC) Congress, taking place August 29 – September 1, 2025, in Madrid, Spain. These new insights offer an in-depth look at both clinical trial results and real-world patient outcomes for Camzyos (mavacamten) and other heart health treatments, strengthening BMS’s reputation as a leader in the field of cardiovascular medicine.

A Focus on Camzyos

Camzyos (mavacamten) has become a focal point in the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). As “the first and only available cardiac myosin inhibitor supported by robust long-term extension and real-world effectiveness data,” Camzyos demonstrates potential benefits in relieving symptoms, improving functional capacity, and positively impacting cardiac structure. According to Roland Chen, MD, senior vice president of drug development for Immunology and Cardiovascular Medicines at BMS, “We are deeply committed to advancing life-changing therapies for patients, including those living with symptomatic obstructive HCM.”

Real-World Insights: COLLIGO-HCM

One of the highlights of the upcoming congress is the presentation of real-world outcomes from COLLIGO-HCM, a global observational study encompassing patient populations in the United States, Canada, the United Kingdom, Australia, and Israel. This analysis aims to shed light on the day-to-day effectiveness and safety of Camzyos in diverse healthcare settings, offering important insight into how this therapy can address the needs of oHCM patients worldwide.

Pooled Phase 3 Findings

Beyond COLLIGO-HCM, BMS will showcase a pooled analysis of Camzyos monotherapy from four Phase 3 clinical trials. These trials foster a deeper understanding of the drug’s impact as a standalone treatment, including its ability to alleviate symptoms and improve quality of life. The data underscores the significance of Camzyos in addressing key challenges faced by patients with obstructive HCM.

Breaking New Ground: ODYSSEY-HCM

A late-breaking presentation will feature topline results from ODYSSEY-HCM, a Phase 3 randomized, double-blind, placebo-controlled trial involving 580 adult patients with symptomatic New York Heart Association class II-III non-obstructive hypertrophic cardiomyopathy (nHCM). This study is both the largest and longest-duration trial completed to date for nHCM, opening the door to a new frontier in therapy for a subgroup of patients underserved by current treatment options.

The Broader Cardiovascular Portfolio

While Camzyos takes center stage, the BMS-Pfizer Alliance will also present findings on Eliquis (apixaban). These include investigations into atrial fibrillation detection, potentially informing effective strategies for stroke prevention. The breadth of data presented reinforces BMS’s multi-pronged approach to cardiovascular health, reflecting what the company describes as a “70-year legacy” in developing life-changing treatments.

Conclusion

Taken together, Bristol Myers Squibb’s upcoming presentations at the ESC Congress 2025 underscore the company’s enduring commitment to the cardiovascular field. From real-world insights to the largest nHCM trial completed to date, BMS aims to advance patient care, refine treatment approaches for hypertrophic cardiomyopathy, and elevate our collective understanding of heart health. As new data and analyses continue to emerge, these findings may mark another milestone in the ever-evolving quest to improve outcomes for patients living with complex cardiovascular conditions.